Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Apr 10, 2017; 8(2): 100-105
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.100
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.100
Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate
Enrique Grande, Olga Martínez-Sáez, Pablo Gajate-Borau, Teresa Alonso-Gordoa, Medical Oncology Department, Ramón y Cajal University Hospital, 28034 Madrid, Spain
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest statement: Grande E has served as advisor and delivered lectures for Pfizer, IPSEN, and Eisai; Martínez-Sáez O, Gajate-Borau P and Alonso-Gordoa T declares no conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Enrique Grande, MD, PhD, Medical Oncology Department, Ramón y Cajal University Hospital, Ctra. Colmenar Viejo km 9100, 28034 Madrid, Spain. egrande@oncologiahrc.com
Telephone: +34-91-3368263 Fax: +34-91-3369181
Received: December 6, 2016
Peer-review started: December 7, 2016
First decision: February 15, 2017
Revised: February 26, 2017
Accepted: March 12, 2017
Article in press: March 13, 2017
Published online: April 10, 2017
Processing time: 121 Days and 12.7 Hours
Peer-review started: December 7, 2016
First decision: February 15, 2017
Revised: February 26, 2017
Accepted: March 12, 2017
Article in press: March 13, 2017
Published online: April 10, 2017
Processing time: 121 Days and 12.7 Hours
Core Tip
Core tip: The landscape of renal cell carcinoma has dramatically changed in the last decade. Today, at least 6 agents are approved after failure with cytokines, sunitinib or pazopanib in first line treatment. Lack of reliable biomarkers to select the best treatment in daily practice is somewhat frustrating. Therefore, our decisions in real practice are based on safety profiles, patient’ co-morbidities and physician experience or preference. Here we debate the pros and cons of the tumor-growth rate as a tool to select second line systemic treatment after failure to a prior tyrosine kinase-inhibitor in patients with advanced renal cell carcinoma.